RSS | Login | Register

INFED

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare INFED to:

Generic Name for INFED

Iron (as dextran complex) 50mg/mL; soln for IV or IM inj.

Legal Classification:

Pharmacological Class for INFED

Hematinic.

Manufacturer of INFED

Watson Pharmaceuticals, Inc.

Indications for INFED

Iron deficiency where oral therapy is unsatisfactory or impossible.

Adults and Children:

Give by IV or by deep IM (into upper outer quadrant of buttock only) inj. Administer 0.5mL test dose first; if no signs/symptoms of anaphylactic-type reactions, may give full therapeutic dose. Iron deficiency anemia: determine total dose based on hemoglobin and body weight (see literature). Iron replacement for blood loss: Replacement iron (in mg) = blood loss (in mL) X hematocrit. Max daily doses: <5kg: 0.5mL (25mg), <10kg: 1mL (50mg), ≥10kg: 2mL (100mg).

Contraindications for INFED

Anemias not associated with iron deficiency.

Warnings/Precautions for INFED

Monitor for signs/symptoms of anaphylactic-type reactions, esp. in patients with history of drug allergies, asthma; have epinephrine available. Avoid large IV doses: higher incidence of adverse events. Severe hepatic impairment. Avoid during acute phase of infectious kidney disease. Dialysis. Cardiovascular disease. May reactivate quiescent rheumatoid arthritis. Neonates (avoid during first 4 months). Pregnancy (Cat. C). Nursing mothers.

Interactions for INFED

Concomitant ACE inhibitors may increase the risk for anaphylactic-type reactions. May falsely elevate serum bilirubin or decrease serum calcium levels.

Adverse Reactions for INFED

See literature. Anaphylactic reactions (may be fatal; even if test dose was tolerated), cardiovascular events, pruritus, GI upset, arthralgia, arthritis, inj site reactions, others; possible IM inj site tumors, sepsis in neonates.

How is INFED supplied?

Vials (2mL)—10

Related Disease:

Anemia

BiferaRx iron supplement available

June 15, 2010

Alaven has made available BiferaRx, a prescription iron supplement that contains heme iron and non-heme iron.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Vpriv available for Type 1 Gaucher disease

March 01, 2010

Shire announced that Vpriv (velaglucerase alfa for injection) has been FDA approved and made available for the treatment of Type 1 Gaucher disease.

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

FDA announces safety plan for erythropoiesis-stimulating agents

February 16, 2010

The FDA has approved a risk management program to inform healthcare providers and patients about the risks of erythropoiesis-stimulating agents (ESAs).